News

January 20, 2020January 20, 2020

Leronlimab Combo Shows Promise for Metastatic TNBC in Early Phase 1b/2 Trial Data

News

Investigational therapy leronlimab is showing promise as a potential therapy for people with CCR5-positive metastatic triple-negative breast cancer (mTNBC), early data from a Phase 1b/2 clinical trial suggest. The open-label ... Read more

January 17, 2020January 21, 2020

New Method Using Sound Waves May Stop Breast Cancer Spread in Lymph Nodes, Mouse Study Shows

News

A new method that uses sound waves to release chemotherapy in lymph nodes invaded by breast cancer cells could offer a safer option to other, more invasive techniques, according to results ... Read more

January 14, 2020January 22, 2020

CytoDyn Files for FDA Breakthrough Therapy Status for Leronlimab for Metastatic TNBC

News

CytoDyn has requested breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy leronlimab (PRO 140) as an adjuvant treatment for metastatic triple-negative breast cancer (TNBC). ... Read more

January 13, 2020January 13, 2020

Certain Genomic Tests May Soon Be Reimbursable for Breast Cancer Patients in Germany

News

Techniker Krankenkasse, one of the largest healthcare insurers in Germany, will begin reimbursing their breast cancer patients for genomic tests, announced Agendia, a diagnostics company that offers a test called MammaPrint. ... Read more

January 10, 2020January 10, 2020

Keytruda, Imprime PGG Combo Increases Overall Survival in Metastatic Triple-negative BC, Data Show

News

Treatment with Biothera Pharmaceutical‘s Imprime PGG appears to increase the sensitivity of chemotherapy-resistant metastatic triple-negative breast cancers (mTNBC) to the immune checkpoint inhibitor Keytruda (pembrolizumab), interim data from a Phase 2 study ... Read more

January 8, 2020January 8, 2020

Arimidex ‘Highly Effective’ at Reducing Long-term Breast Cancer Rates in At-risk Women, Study Finds

News

Postmenopausal women at increased risk of breast cancer are half as likely to develop the cancer after a five-year treatment with Arimidex (anastrozole), compared to a placebo, and this reduced ... Read more

January 2, 2020January 3, 2020

Enhertu Gets FDA Approval for Treatment of Advanced HER2-positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) approved Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received at least two prior ... Read more

December 30, 2019January 6, 2020

Seattle Genetics Seeks Tucatinib’s Approval by FDA for Advanced HER2-positive Breast Cancer

News

Seattle Genetics has submitted an application requesting U.S. Food and Drug Administration (FDA) approval for its investigational therapy tucatinib, in combination with trastuzumab and Xeloda (capecitabine), for treating people with locally advanced ... Read more

December 19, 2019January 15, 2020

FDA Grants Breakthrough Therapy Status to Tucatinib for Advanced HER2-Positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Seattle Genetics’ tucatinib, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with locally ... Read more

December 18, 2019January 15, 2020

TAVO Boosts Responses to Keytruda in Triple-negative Breast Cancer Patients, Interim Phase 2 Data Show

News

Treatment with TAVO (intratumoral IL-12) appears to increase the sensitivity of previously treated advanced triple-negative breast cancers (mTNBC) to the immune checkpoint inhibitor Keytruda (pembrolizumab), interim data from a Phase ... Read more